[Molecular target drugs for malignant lymphoma].
According to revised WHO classification for lymphoid malignancies, biological differences among pathological subtypes of lymphomas could be key points for molecular target therapies. For B cell lymphomas, CD20, CD22, CD19 can be molecules for target therapies, whereas there are not so many molecular targets in T cell lymphomas yet. However, novel molecular target drugs are developing from home and abroad. Especially, inhibitors for mTOR, IKK/JAK, HDAC, proteasome, HSP90, and proapoptotic molecules are developing in clinical trials for B cell- and T cell-lymphomas, and their anti-lymphoma activities will be considerably promising. Moreover, immunomodulatory drugs such as lenalidomide are also tried to investigate the effect on lymphomas. Here, some novel molecular drugs currently under development will be reviewed about their anti-lymphoma effects.
Terui
Yasuhito
Y
Department of Hematology/Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research.
D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D058990:Molecular Targeted Therapy